The oral ghrelin agonist TZP-102 was tested in a phase IIb randomized trial in 201 patients with diabetic gastroparesis. TZP-102 administered at 10 mg or 20 mg daily for 12 weeks had no substantial effect on diabetic gastroparesis symptoms as determined using the Daily Diary of Gastroparesis Symptoms Questionnaire, when compared with patients given placebo. However, a marked symptom improvement was observed in all patients over the trial period.
ORIGINAL RESEARCH PAPER
McCallum, R. W. et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol. Motil. doi:10.1111/nmo.12184
About this article
Cite this article
Efficacy of oral ghrelin agonist in diabetic gastroparesis. Nat Rev Gastroenterol Hepatol 10, 502 (2013). https://doi.org/10.1038/nrgastro.2013.157